Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 191 - 200 of 337

Selected Filters:
7 July 2022

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

External Link
7 July 2022

DISCOVER Trial Factsheet

This factsheet provides details on the DISCOVER trial to assess whether F/TAF (trade name Descovy) is as safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product.

Community/Advocacy, Research

External Link
7 July 2022

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

External Link
7 July 2022

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies

External Link
7 July 2022

Descovy for PrEP – FDA Supplemental Approval

This letter from the US Food and Drug Administration outlines supplemental approval granted to Descovy, an oral PrEP medication.

Normative Guidance/Policies

External Link
7 July 2022

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic recommendations across different ages, populations and settings, bringing together all relevant WHO guidance on HIV produced since 2016. It serves as an update to the previous edition of the consolidated guidelines on HIV.

Normative Guidance/Policies, Service Delivery

External Link
7 July 2022

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Community/Advocacy

External Link
7 July 2022

Easier and Equitable Access to PrEP: How DSD can help get us there

Easier and Equitable Access to PrEP is an article written by AVAC's Director of Product Introduction and Access, Jessica Rodrigues. It elaborates on the impact of oral PrEP on the HIV pandemic and the current modifications underway to make oral PrEP more accessible to people. Differentiated Services Delivery is a method that provides oral PrEP…

Demand Creation/Marketing, Service Delivery

External Link
7 July 2022

Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study

Widespread adoption of WHO PrEP recommendations coincided with a global increase in PrEP use. Although the 2020 global PrEP target will be missed, strong future growth in PrEP use is possible. New PrEP products could expand the PrEP user base, and, with greater expansion of oral PrEP, further adoption of WHO PrEP recommendations, and simplified…

Normative Guidance/Policies, Research, Service Delivery

External Link
7 July 2022

Health system adaptations and considerations to facilitate optimal oral pre-exposure prophylaxis scale-up in sub-Saharan Africa

Countries in sub-Saharan Africa have progressively scaled up oral PrEP as part of combination HIV prevention. Initial scale-up efforts have generated progress, drawing lessons from existing HIV interventions, such as antiretroviral therapy and biomedical prevention. However, beset by unprepared health systems, scale-up has been slow. This review synthesises literature on essential considerations for PrEP scale-up,…

Normative Guidance/Policies, Research, Service Delivery

External Link